Iovance (NASDAQ: IOVA) COO Bilinsky logs 31,246 RSUs vested and tax withholding shares

Rhea-AI Filing Summary

IOVANCE BIOTHERAPEUTICS, INC. Chief Operating Officer Igor Bilinsky reported the vesting of 31,246 restricted stock units on March 5, 2026, which were converted into an equal number of common shares at no exercise price.

To cover mandatory tax withholding on this RSU vesting, 16,628 common shares were withheld by the company at a reference price of $4.58 per share, which the disclosure states is not an open market sale. After these transactions, Bilinsky directly held 125,766 common shares and 62,504 RSUs. The remaining RSUs from this March 5, 2025 grant are scheduled to vest in equal quarterly installments, with each unit representing the right to receive one share of common stock.

Insider Trade Summary

31,246 shares exercised/converted

Mixed 3 txns

Insider BILINSKY IGOR

Role Chief Operating Officer

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units	31,246	$0.00	--
Exercise	Common Stock	31,246	$0.00	--
Tax Withholding	Common Stock	16,628	$4.58	$76K

Holdings After Transaction: Restricted Stock Units — 62,504 shares (Direct); Common Stock — 142,394 shares (Direct)

Footnotes (1)

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. Represents common stock remaining after deducting the common stock withheld for taxes. Each RSU represents a contingent right to receive one share of the Issuer's common stock. The remaining RSUs will vest in equal quarterly installments. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BILINSKY IGOR

(Last) (First) (Middle)

C/O IOVANCE BIOTHERAPEUTICS, INC.

825 INDUSTRIAL ROAD, SUITE 100

(Street)

SAN CARLOS CA 94070

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
IOVANCE BIOTHERAPEUTICS, INC. [ IOVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Operating Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/05/2026		M		31,246	A	$0	142,394	D
Common Stock(2)	03/05/2026		F		16,628	D	$4.58	125,766(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(4)	03/05/2026		M			31,246	(5)	(5)	Common stock	31,246	$0.00	62,504(6)	D

Explanation of Responses:

1. Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.

2. Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.

3. Represents common stock remaining after deducting the common stock withheld for taxes.

4. Each RSU represents a contingent right to receive one share of the Issuer's common stock.

5. The remaining RSUs will vest in equal quarterly installments.

6. Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.

	/s/ Igor Bilinsky	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did IOVANCE (IOVA) COO Igor Bilinsky report in this Form 4 filing?

Igor Bilinsky reported RSU vesting and related share movements. 31,246 RSUs vested and converted to common stock, with some shares withheld to cover taxes, changing his reported holdings in Iovance common stock and restricted stock units.

How many IOVANCE (IOVA) RSUs vested for Igor Bilinsky and what did they become?

A total of 31,246 restricted stock units vested for Igor Bilinsky. According to the filing, each RSU represents a right to receive one share, so they were settled into 31,246 shares of Iovance common stock at no exercise price.

Why were 16,628 IOVANCE (IOVA) shares disposed of in this Form 4?

The filing shows 16,628 common shares were disposed of at $4.58 to satisfy mandatory tax withholding on the RSU vesting. Footnotes clarify this was not an open market sale but shares withheld by the issuer for tax obligations.

What are Igor Bilinsky’s IOVANCE (IOVA) common stock holdings after these transactions?

After the reported transactions, Igor Bilinsky directly held 125,766 shares of Iovance common stock. This figure reflects the new shares issued from RSU vesting, minus the portion withheld to cover taxes, as described in the Form 4.

How many IOVANCE (IOVA) RSUs remain for Igor Bilinsky and how will they vest?

Following the vesting event, Bilinsky had 62,504 RSUs remaining from the March 5, 2025 grant. Footnotes state these remaining RSUs are scheduled to vest in equal quarterly installments, with each RSU equal to one share of common stock.

Does this IOVANCE (IOVA) Form 4 indicate any open market stock sales by the COO?

The Form 4 specifies that shares used for tax withholding are not an open market sale. The disposition of 16,628 shares is described as issuer-withheld stock to satisfy tax requirements, not discretionary selling by Igor Bilinsky on the open market.